Washington, D.C. 20549 FORM 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION (I.R.S. Employer Identification No.) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File No. 001-41293 ASPIRE BIOPHARMA HOLDINGS, INC. (Exact name of registrant as specified in its charter) Dela ...

Financial Performance - The company reported a net income of $184,662 for the three months ended March 31, 2025, compared to a net income of $755,500 for the same period in 2024, indicating a decrease of about 76%[13]. - Basic and diluted net income per ordinary share subject to possible redemption was $0.03 for the three months ended March 31, 2025, down from $0.08 in the same period of 2024[13]. - Net income for the three months ended March 31, 2025, was $184,662, compared to $755,500 for the same period in 2024, indicating a significant decrease in profitability[61]. - Basic and diluted net income per share for the three months ended March 31, 2025, was $0.03, down from $0.08 for the same period in 2024[61]. - As of March 31, 2025, the accumulated deficit increased to $(2,367,937) from $(1,476,823) as of December 31, 2024, reflecting a worsening financial position[15]. Assets and Liabilities - As of March 31, 2025, total assets decreased to $43,602,847 from $73,814,933 as of December 31, 2024, representing a decline of approximately 41%[10]. - Total current liabilities increased to $1,685,746 as of March 31, 2025, from $816,994 as of December 31, 2024, marking an increase of approximately 106%[10]. - Cash held in the Trust Account decreased to $43,594,825 as of March 31, 2025, from $73,784,549 as of December 31, 2024, a reduction of about 41%[10]. - The Company has a working capital deficit of $1,677,724 as of March 31, 2025[40]. - The total amount due to a related company as of March 31, 2025, was $472,926, an increase from $289,780 as of December 31, 2024[80]. Initial Public Offering (IPO) - The Initial Public Offering generated gross proceeds of $69,000,000, with offering costs amounting to $2,070,665 and deferred underwriting commissions of $690,000[22]. - The Company completed its Initial Public Offering on December 6, 2023, raising gross proceeds of $69,000,000 from the sale of 6,900,000 Units at $10.00 per Unit[69]. - The IPO generated gross proceeds of $60,000,000 from the sale of 6,000,000 units at an offering price of $10.00 per unit[125]. - An additional $9,000,000 was raised through the full exercise of the Over-Allotment Option by underwriters[125]. - The company incurred $1,380,000 in underwriting discounts and $550,000 in other costs related to the IPO[128]. Business Operations and Future Plans - The company had not commenced any operations as of March 31, 2025, and all activities were related to its formation and Initial Public Offering[21]. - The company anticipates targeting small cap companies in healthcare innovation for future business combinations[20]. - The Company has entered into a definitive Business Combination Agreement with United Hydrogen Group Inc. and its subsidiaries[35]. - Management has raised substantial doubt about the company's ability to continue as a going concern if the initial business combination is not completed within the prescribed time[112]. Cash Flow and Liquidity - Cash flows from operating activities resulted in a net cash used of $224,009 for the three months ended March 31, 2025, compared to $166,970 for the same period in 2024[17]. - The Company’s liquidity is primarily supported by net proceeds from the Initial Public Offering and Private Placement[41]. - As of March 31, 2025, the Company had $7,345 in its bank account[40]. - The Trust Account held $43,594,825 as of March 31, 2025, while the company had a working capital deficit of approximately $1,677,724[110]. Shareholder Information - A total of 2,904,267 shares were redeemed at approximately $10.77 per share, amounting to an aggregate of about $31.27 million[37]. - The Company’s ordinary shares subject to possible redemption totaled 3,995,773 at the redemption amount as of March 31, 2025[55]. - As of March 31, 2025, there were 2,126,000 ordinary shares issued and outstanding, excluding 3,995,773 and 6,900,000 shares subject to possible redemption[85]. - The Sponsor purchased an aggregate of 332,000 Private Units at a price of $10.00 per Private Unit, totaling $3,320,000[72]. Regulatory and Compliance - The company filed a Registration Statement on Form S-1/A on July 24, 2023, which includes specimen unit, ordinary share, and rights certificates[4.1][4.2][4.3]. - Certifications of the Principal Executive Officer and Principal Financial Officer were completed in accordance with the Sarbanes-Oxley Act of 2002[31.1][31.2]. - The Inline XBRL Instance Document and related taxonomy extension documents were filed, indicating compliance with SEC requirements[101.INS][101.SCH][101.CAL][101.DEF][101.LAB][101.PRE].

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41880 AIMEI HEALTH TECHNOLOGY CO., LTD UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR (I.R.S. Employer Identification No.) 10 East 53rd Street, Suite 3001 New York, NY 10022 (Address of ...

EX-99.1 2 job_ex991.htm PRESS RELEASE EXHIBIT 99.1 GEE Group Announces Results for the Fiscal 2025 Second Quarter and YTD Jacksonville, FL / May 14, 2025 / Accesswire / GEE Group Inc. (NYSE American: JOB) together with its subsidiaries (collectively referred to as the "Company," "GEE Group," "our" or "we"), a provider of professional staffing services and human resource solutions, today announced consolidated results for the fiscal 2025 second quarter and year to date periods ended March 31, 2025. The Compa ...

Exhibit 99.1 CONTINEUM THERAPEUTICS REPORTS FIRST-QUARTER 2025 FINANCIAL RESULTS; AFFIRMS KEY CLINICAL DEVELOPMENT MILESTONES - Topline data from PIPE-791 Phase 1b positron emission tomography (PET) trial expected in the second quarter of 2025 About Contineum Therapeutics Contineum Therapeutics (Nasdaq: CTNM) is a clinical-stage biopharmaceutical company pioneering novel, oral small molecule therapies for NI&I indications with significant unmet need. Contineum is advancing a pipeline of internally-developed ...

[Financial and Operational Highlights](index=1&type=section&id=Financial%20and%20Operational%20Highlights) This section summarizes SS Innovations' strong financial performance in Q1 2025 and outlines key business and strategic advancements [First Quarter 2025 Overview](index=1&type=section&id=First%20Quarter%202025%20Overview) SS Innovations reported record quarterly revenue of $5.1 million for Q1 2025, a 40.8% increase year-over-year, driven by higher sales of its SSi Mantra 3 surgical robotic system Q1 2025 Financial Highlights (vs. Q1 2024) | Metric | Q1 2025 | Q1 2024 | Change | | :--- | :--- | :--- | :--- | | Revenue | $5.1 million | $3.6 million | +40.8% | | Gross Profit | $1.1 million | $0.7 million | +49.3% | | Gross Margin | 21.23% | 20.02% | +121 bps | | Net Loss | $(5.7) million | $(9.8) million | Narrowed | | Net Loss per Share | $(0.03) | $(0.06) | Narrowed | | SSi Mantra Installations | 15 units | 9 units | +66.7% | Q1 2025 Revenue Breakdown and Operational Metrics (vs. Q1 2024) | Category | Q1 2025 | Q1 2024 | % Change | | :--- | :--- | :--- | :--- | | System sales | $4,502,482 | $3,494,759 | +28.8% | | Instrument sales | $477,208 | $118,515 | +302.7% | | Warranty sales | $122,504 | $9,407 | +1,202.3% | | **Total revenue** | **$5,120,610** | **$3,637,693** | **+40.8%** | | SSi Mantra installations | 15 | 9 | +67% | | Cumulative installed base | 78 | 24 | +225% | | SSi Mantra surgeries | 787 | 361 | +118% | | Cumulative surgeries | 3,568 | 981 | +264% | - The company ended the quarter with **$15.9 million** in cash and cash equivalents and zero long-term debt[5](index=5&type=chunk) [Business and Strategic Developments](index=1&type=section&id=Business%20and%20Strategic%20Developments) Following the quarter, the company uplisted its stock to the Nasdaq Capital Market, while focusing on global expansion and key operational milestones - The company is on track to submit a De Novo application for the SSi Mantra 3 system to the U.S. Food and Drug Administration (FDA) by the end of July 2025[1](index=1&type=chunk)[6](index=6&type=chunk) - SS Innovations is pursuing a European Union CE Mark decision, with a target of late 2025[6](index=6&type=chunk) - Subsequent to the quarter end, on April 25, 2025, the company's common stock was uplisted to The Nasdaq Capital Market®[3](index=3&type=chunk) - Key Q1 achievements include: - The SSi Mantra 3 system enabled the world's first robotic cardiac telesurgery - The company debuted a state-of-the-art mobile telesurgery unit in India - Received medical device regulatory approvals in the Philippines and Ukraine[9](index=9&type=chunk) [Financial Statements](index=4&type=section&id=Financial%20Statements) This section presents the condensed consolidated balance sheets, statements of operations, and cash flows for SS Innovations, highlighting key financial positions and performance metrics [Condensed Consolidated Balance Sheets](index=4&type=section&id=Condensed%20Consolidated%20Balance%20Sheets) As of March 31, 2025, total assets grew to $63.5 million from $42.4 million at year-end 2024, largely due to a significant increase in cash and inventory Balance Sheet Summary | Account | March 31, 2025 | December 31, 2024 | | :--- | :--- | :--- | | Cash and cash equivalents | $15,873,217 | $466,500 | | Total Current Assets | $47,619,943 | $27,416,291 | | **Total Assets** | **$63,456,961** | **$42,385,213** | | Total Current Liabilities | $14,996,713 | $21,330,222 | | **Total Liabilities** | **$22,902,671** | **$28,928,110** | | **Total Stockholders' Equity** | **$40,554,290** | **$13,457,103** | [Condensed Consolidated Statements of Operations](index=5&type=section&id=Condensed%20Consolidated%20Statements%20of%20Operations) For the three months ended March 31, 2025, revenues increased 40.8% to $5.1 million, with a significant reduction in stock compensation expense leading to a narrowed net loss of $5.7 million Statement of Operations Summary (Three Months Ended) | Account | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Total Revenue | $5,120,610 | $3,637,693 | | Gross Profit | $1,087,208 | $728,182 | | Total Operating Expenses | $7,009,061 | $10,560,501 | | Loss from Operations | $(5,921,853) | $(9,832,319) | | **Net Loss** | **$(5,681,353)** | **$(9,841,753)** | | Net Loss Per Share (basic and diluted) | $(0.03) | $(0.06) | - Stock compensation expense decreased significantly to **$2.4 million** in Q1 2025 from **$7.1 million** in Q1 2024, which was a primary driver for the reduction in net loss[15](index=15&type=chunk) [Condensed Consolidated Statements of Cash Flows](index=6&type=section&id=Condensed%20Consolidated%20Statements%20of%20Cash%20Flows) In Q1 2025, the company used $6.1 million in cash from operating activities, offset by $22.4 million provided by financing activities, resulting in a net increase in cash of $15.4 million Cash Flow Summary (Three Months Ended) | Activity | March 31, 2025 | March 31, 2024 | | :--- | :--- | :--- | | Net cash used in operating activities | $(6,103,374) | $(2,671,918) | | Net cash used in investing activities | $(872,804) | $(127,255) | | Net cash provided by financing activities | $22,406,019 | $2,638,259 | | **Net change in cash** | **$15,429,841** | **$(160,914)** | | Cash and cash equivalents at end of period | $22,078,788 | $6,895,580 | - Financing activities were primarily driven by **$28 million** in proceeds from the issuance of convertible notes to a principal shareholder[17](index=17&type=chunk) - As a supplemental disclosure, **$30.6 million** of convertible notes, including interest, were converted into common stock during the period[17](index=17&type=chunk) [Company and Product Overview](index=2&type=section&id=Company%20and%20Product%20Overview) This section provides an overview of SS Innovations International, Inc., its mission to democratize robotic surgery, and details its flagship SSi Mantra surgical robotic system [About SS Innovations](index=2&type=section&id=About%20SS%20Innovations) SS Innovations International, Inc. is an American company, headquartered in India, that develops surgical robotic technologies with a mission to make robotic surgery affordable and accessible globally - The company's vision is to democratize robotic surgery by making it affordable and accessible to a larger segment of the global population[8](index=8&type=chunk) - The product portfolio includes the SSi Mantra surgical robotic system and SSi Mudra surgical instruments, which support various procedures including robotic cardiac surgery[8](index=8&type=chunk) [About the SSi Mantra](index=3&type=section&id=About%20the%20SSi%20Mantra) The SSi Mantra is a modular, multi-arm surgical robotic system designed for user-friendliness, featuring advanced technologies and clinical validation across over 100 surgical procedures in India - The system is modular with 3 to 5 robotic arms and features an open-faced ergonomic surgeon command center with a large 3D 4K monitor[10](index=10&type=chunk) - It utilizes over 40 different types of robotic endo-surgical instruments to support specialties including cardiac surgery[10](index=10&type=chunk) - The SSi Mantra has been clinically validated in India in more than 100 different types of surgical procedures[10](index=10&type=chunk)

united states Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q (Mark One) ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the transition period from …… to ……. Commission File Number 0-12114 Cadiz Inc. (Exact name of registrant specified in its charter) Delaware 77-0313235 (State or other jurisdiction of ( ...

Cadiz Inc. (Exact name of registrant specified in its charter) Delaware 77-0313235 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) united states Securities and Exchange Commission Washington, D. C. 20549 FORM 10-Q (Mark One) ☑ Quarterly Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the quarterly period ended March 31, 2025 OR ☐ Transition Report Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for t ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 or ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-40612 (Exact name of registrant as specified in its charter) Non-accelerated filer ☒ Smaller reporting compan ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Delaware 26-4231384 (State or other jurisdiction of incorporation or organization) (IRS Employer Identification No.) 303A College Road East, Princeton, NJ 08540 For the quarterly period ended March 31, 2025 ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ...